Additionally, the 36-month beta value for MBRX is 1.85. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MBRX is 2.74M and currently, short sellers hold a 4.47% ratio of that float. The average trading volume of MBRX on November 15, 2024 was 33.32K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MBRX) stock’s latest price update
Moleculin Biotech Inc (NASDAQ: MBRX)’s stock price has soared by 23.11 in relation to previous closing price of 2.51. Nevertheless, the company has seen a gain of 32.05% in its stock price over the last five trading days. prnewswire.com reported 2024-11-14 that Amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) in the first quarter of 2025 Company releases Virtual Investor “What This Means” segment discussing the amended protocol; Available here HOUSTON, Nov. 14, 2024 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has amended the clinical trial protocol with the U.S. Food and Drug Administration (“FDA”) for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML) (MB-108). This Phase 3 “MIRACLE” trial (derived from M olecul i n R /R AML A nnAraC Cl inical E valuation) will be a global trial, including sites in the US.
MBRX’s Market Performance
Moleculin Biotech Inc (MBRX) has experienced a 32.05% rise in stock performance for the past week, with a 27.69% rise in the past month, and a 26.64% rise in the past quarter. The volatility ratio for the week is 11.70%, and the volatility levels for the past 30 days are at 8.79% for MBRX. The simple moving average for the past 20 days is 20.87% for MBRX’s stock, with a -29.42% simple moving average for the past 200 days.
Analysts’ Opinion of MBRX
Many brokerage firms have already submitted their reports for MBRX stocks, with Oppenheimer repeating the rating for MBRX by listing it as a “Outperform.” The predicted price for MBRX in the upcoming period, according to Oppenheimer is $14 based on the research report published on July 18, 2022 of the previous year 2022.
MBRX Trading at 23.16% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.38% of loss for the given period.
Volatility was left at 8.79%, however, over the last 30 days, the volatility rate increased by 11.70%, as shares surge +30.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.10% upper at present.
During the last 5 trading sessions, MBRX rose by +32.05%, which changed the moving average for the period of 200-days by -59.13% in comparison to the 20-day moving average, which settled at $2.56. In addition, Moleculin Biotech Inc saw -76.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MBRX starting from Foster Jonathan P., who purchase 28,986 shares at the price of $0.69 back on Dec 26 ’23. After this action, Foster Jonathan P. now owns 80,556 shares of Moleculin Biotech Inc, valued at $20,000 using the latest closing price.
George Robert E., the Director of Moleculin Biotech Inc, purchase 14,493 shares at $0.69 during a trade that took place back on Dec 26 ’23, which means that George Robert E. is holding 14,660 shares at $10,000 based on the most recent closing price.
Stock Fundamentals for MBRX
Current profitability levels for the company are sitting at:
- -71.22 for the present operating margin
- 0.76 for the gross margin
The net margin for Moleculin Biotech Inc stands at -74.26. The total capital return value is set at -1.62. Equity return is now at value -141.49, with -95.84 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -62.02. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -65.87.
Currently, EBITDA for the company is -29.5 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In conclusion, Moleculin Biotech Inc (MBRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
